Endoglin inhibits ERK-induced c-Myc and cyclin D1 expression to impede endothelial cell proliferation

Biochemical and Biophysical Research Communications

Volumn 424, Issue 3, 2012, Pages 620-623

  Pan, Christopher C ^a   Bloodworth, Jeffrey C ^a   Mythreye, Karthikeyan ^c   Lee, Nam Y ^a,b  

^a Division of Pharmacology   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

arrestin2; C Myc; Endoglin; ERK; Smads; TGF

Indexed keywords

BETA ARRESTIN 2; CYCLIN D1; ENDOGLIN; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; ENDOTHELIUM CELL; ENZYME ACTIVATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; VASCULAR ENDOTHELIUM;

ANTIGENS, CD; CELL LINE; CELL PROLIFERATION; CYCLIN D1; ENDOTHELIUM, VASCULAR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTORS, CELL SURFACE; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 84864781306     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.06.163     Document Type: Article

References (22)

1. Abdalla S.A., Letarte M. Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease. J. Med. Genet. 2006, 43(2):97-110.
2. Pardali E., Goumans M.J., ten Dijke P. Signaling by members of the TGF-β family in vascular morphogenesis and disease. Trends Cell Biol. 2010, 20:556-567.
3. Shovlin C.L., Guttmacher A.E., Buscarini E., Faughnan M.E., Hyland R.H., Westermann C.J., Kjeldsen A.D., Plauchu H. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am. J. Med. Genet. 2000, 91(1):66-67.
4. Otrock Z.K., Mahfouz R.A., Makarem J.A., Shamseddine A.I. Understanding the biology of angiogenesis: review of the most important molecular mechanisms. Blood Cells Mol. Dis. 2007, 39(2):212-220.
5. Lebrin F., Goumans M.J., Jonker L., Carvalho R.L., Valdimarsdottir G., Thorikay M., Mummery C., Arthur H., Dijke P.T. Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J. 2004, 23:4018-4028.
6. Lebrin F., Deckers M., Bertolino P., Dijke P. TGF-beta receptor function in the endothelium. Cardiovasc. Res. 2004, 65(3):599-608.
7. Bernabeu C., Conley B.A. Novel biochemical pathways of endoglin in vascular cell physiology. J. Cell. Biochem. 2007, 102:1375-1388.
8. Derynck R., Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425:577-584.
9. Guerrero-Esteo M., Sanchez-Elsner T., Letamendia A., Bernabeu C. Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor- receptors I and II. J. Biol. Chem. 2002, 277(32):29197-29209.
10. Conley B.A., Koleva R., Smith J.D., Kacer D., Zhang D., Bernabéu C., Vary C.P. Endoglin controls cell migration and composition of focal adhesions: function of the cytosolic domain. J. Biol. Chem. 2004, 279(26):27440-27449.
11. Sanz-Rodriguez F., Guerrero-Esteo M., Botella L.M., Banville D., Vary C.P., Bernabéu C. Endoglin regulates cytoskeletal organization through binding to ZRP-1, a member of the Lim family of proteins. J. Biol. Chem. 2004, 279(31):32858-32868.
12. Lee N.Y., Blobe G.C. The interaction of endoglin with beta-arrestin2 regulates transforming growth factor-beta-mediated ERK activation and migration in endothelial cells. J. Biol. Chem. 2007, 282(29):21507-21517.
13. Lee N.Y., Ray B., How T., Blobe G.C. Endoglin promotes transforming growth factor β-mediated Smad 1/5/8 signaling and inhibits endothelial cell migration through its association with GIPC. J. Biol. Chem. 2008, 283(47):32527-32533.
14. Park S.O., Lee Y.J. ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2. Blood 2008, 111:633-642.
15. Pece-Barbara N., et al. Endoglin null endothelial cells proliferate faster and are more responsive to transforming growth factor beta 1 with higher affinity receptors and an activated ALK1 pathway. J. Biol. Chem. 2005, 280(30):27800-27808.
16. Dallas N.A., Samuel S., Xia L., Fan F., Gray M.J., Lim S.J., Ellis L.M. Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin. Cancer Res. 2008, 14:1931-1937.
17. Koleva R.I., Conley B.A., Romero D., Riley K.S., Marto J.A., Lux A., Vary C.P. Endoglin structure and function determinants of endoglin phosphorylation by transforming growth factor-β receptors. J. Biol. Chem. 2006, 19(281):25110-25123.
18. Fonsatti E., et al. Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene 2003, 22(42):6557-6563.
19. Venkatesha S., et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med. 2006, 12:642-649.
20. Funaba M., Zimmerman C.M., Mathews L.S. Modulation of Smad2-mediated signaling by extracellular signal-regulated kinase. J. Biol. Chem. 2002, 277(44):41361-41368.
21. Massague J. Integration of Smad and MAPK pathways: a link and linker revisited. Genes Dev. 2003, 17:2993-2997.
22. Massague J., Seoane J., Wotton D. Smad transcription factors. Genes Dev. 2005, 19:2783-2810.